Corcept Therapeutics (CORT) announced that the U.S. Food and Drug Administration has approved Lifyorli in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab. “Lifyorli is the first FDA-approved selective glucocorticoid receptor antagonist,” the company stated.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?
- Corcept Therapeutics: Early Lifyorli Approval and Robust Long‑Term Sales Outlook Underpin Buy Rating and $60 Target
- Corcept Therapeutics price target lowered to $60 from $67 at H.C. Wainwright
- Corcept Therapeutics rises 28.6%
- Corcept Therapeutics trading resumes